PLSM.US Pulsenmore Ltd. Ordinary Shares
- Market cap
- USD 8.97M
- P/E
- -
- P/B
- 0.61x
- ROE
- -302.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is PLSM.US undervalued?
Graham numberThe Graham number of Pulsenmore Ltd. Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pulsenmore Ltd. Ordinary Shares fundamental analysis
No fundamental analysis for Pulsenmore Ltd. Ordinary Shares yet.
Pulsenmore Ltd. Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pulsenmore Ltd. Ordinary Shares
Pulsenmore Ltd., a medical device company, engages in the research, development, manufacture, marketing, and sale of portable ultrasound solutions. The company provides Pulsenmore ES and Pulsenmore FC products in the United States, the United Kingdom, Northern Ireland, and Europe. The company was incorporated in 2014 and is based in Omer, Israel.
Full company profilePulsenmore Ltd. Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pulsenmore Ltd. Ordinary Shares annual financial statements (ILS; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | - | 1.58M | 10.6M | 6.14M | 9.64M | 40.0M | 25.6M |
| Gross Profit | -243K | -350K | 207K | 3.87M | 39.7K | 2.07M | 33.7M | 9.35M |
| Operating Income | -4.18M | -13.3M | -21.9M | -45.3M | -55.1M | -42.1M | -12.2M | -87.2M |
| EBITDA | -4.31M | -13.3M | -24.8M | -20.1M | -55.0M | -33.3M | -12.7M | -80.8M |
| Net Income | -4.64M | -13.7M | -25.6M | -21.7M | -58.1M | -36.7M | -15.9M | -147M |
| EPS | -0.75 | -2.23 | -4.99 | -3.59 | -9.07 | -5.72 | -2.47 | -23 |
| Balance Sheet | ||||||||
| Total Assets | 6.32M | 9.01M | 167M | 231M | 178M | 142M | 102M | 101M |
| Total Liabilities | 2.37M | 3.74M | 7.76M | 48.8M | 47.7M | 38.4M | 18.8M | 51.9M |
| Shareholders' Equity | 3.95M | 2.89M | 154M | 184M | 131M | 96.7M | 83.1M | 48.7M |
| Cash & Short-term Investments | 4.87M | 6.13M | 153M | 180M | 141M | 104M | 69.1M | 70.3M |
| Total Debt | 2.12M | 1.08M | 1.02M | 6.92M | 5.69M | 3.23M | 1.57M | 34.6M |
| Cash Flow | ||||||||
| Operating Cash Flow | -3.83M | -9.47M | -26.0M | -24.5M | -42.4M | -33.7M | -32.9M | -68.4M |
| Capital Expenditure | 186K | 389K | 774K | 4.41M | 3.89M | 508K | 135K | 563K |
| Free Cash Flow | -4.01M | -9.85M | -26.8M | -28.9M | -46.3M | -34.2M | -33.0M | -69.0M |
| Ratios | ||||||||
| ROE | -117.3% | -475.0% | -16.7% | -11.8% | -44.3% | -37.9% | -19.1% | -302.8% |
| ROA | -73.3% | -152.5% | -15.3% | -9.4% | -32.6% | -25.9% | -15.6% | -146.5% |
| Net Profit Margin | - | - | -1,623.9% | -204.5% | -946.5% | -380.3% | -39.6% | -576.8% |
| Debt to Equity | 0.54x | 0.37x | 0.01x | 0.04x | 0.04x | 0.03x | 0.02x | 0.71x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pulsenmore Ltd. Ordinary Shares dividends
Pulsenmore Ltd. Ordinary Shares has not paid dividends in the last 7 fiscal years.
Who owns Pulsenmore Ltd. Ordinary Shares
- Insiders 35.78%
- Institutions 4.42%
- Public & others 59.80%
- Shares outstanding 6.50M
- Free float 3.42M
Top funds holding PLSM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 2.41K | 0.04% | 0.00% | Aug 2026 |
Top institutions holding PLSM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Aquamarine Financial (Cayman) Ltd | 339K | 5.21% | 0.00% | Sep 2026 |
Pulsenmore Ltd. Ordinary Shares company profile
- Company name
- Pulsenmore Ltd. Ordinary Shares
- Ticker
- PLSM.US
- ISIN
- IL0011767006
- Exchange
- USA Stocks
- Listed since
- Jan 21, 2026
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 71
- Fiscal year end
- December
- Address
- 8 Omarim Street, Omer, Israel
- Phone
- 972 5 2606 2075
- Website
- pulsenmore.com
About Pulsenmore Ltd. Ordinary Shares
Pulsenmore Ltd., a medical device company, engages in the research, development, manufacture, marketing, and sale of portable ultrasound solutions. The company provides Pulsenmore ES and Pulsenmore FC products in the United States, the United Kingdom, Northern Ireland, and Europe. The company was incorporated in 2014 and is based in Omer, Israel.
Pulsenmore Ltd. Ordinary Shares management
8- Dr. Elazar SonnenscheinFounder, CEO & Director · born 1963
- Mr. Eran HirshChief Financial Officer · born 1977
- Mr. Minelu SonnenscheinVice President of R&D · born 1965
- Mr. Meir ShmouelyVice President of Software Development · born 1966
- Mr. Michael HamelsdorfGeneral Counsel & Company Secretary · born 1980
- Ms. Mira Altmark-SoferVice President of Marketing · born 1977
- Prof. Israel MeiznerChief Medical Officer & Member of Scientific Advisory Committee
- Mr. David Gerard WoodsChief Commercial Officer · born 1965